Evidence map›Paper›PMID 24501417›Full record

ArticleJournal of virology2014

Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.

R P Payne, S Branch, H Kløverpris, P C Matthews, C K Koofhethile, T Strong, E Adland, E Leitman, J Frater, T Ndung'u and 19 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Narrative Review Explaining the Role ofInfectious disease reports · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Differential escape of HCV from CD8Journal of viral hepatitis · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Frontiers in pharmacology · 2017
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 7 countries.

R P PayneDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
S Branch
H Kløverpris
P C Matthews
C K Koofhethile
T Strong
E Adland
E Leitman
J Frater
T Ndung'u
E Hunter
R Haubrich
B Mothe
A Edwards
L Riddell
F Chen
P R Harrigan
Z L Brumme
S Mallal
M John
J P Jooste
R Shapiro
S G Deeks
B D Walker
C Brander
C Landis
J M Carlson
J G Prado
P J R Goulder
University of Oxford · GBIrsiCaixa · ESQueen Elizabeth Hospital · BBAIDS Vancouver · CAChurchill Hospital · GBEmory University · USHarvard University · USInstitució Catalana de Recerca i Estudis Avançats · ESKimberley Hospital · ZAMicrosoft (United States) · USMurdoch University · AUNational Health Service · GBOxford BioMedica (United Kingdom) · GBRagon Institute of MGH, MIT and Harvard · USRoyal Berkshire Hospital · GBRoyal Perth Hospital · AUSimon Fraser University · CAUniversity of California, San Diego · USUniversity of California, San Francisco · USUniversity of KwaZulu-Natal · ZA

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
Optimizing CD8+ T-cell responses against C clade HIV infection in subSaharan AfriR01AI046995 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2000 to 2014
$6.8M
Improving Antiretroviral Management for HIVK24AI064086 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAUBRICH, RICHARD H · 2006 to 2015
$1.8M
CIHRMedical Research Council G0501777Medical Research Council G108/626Medical Research Council MR/L006588/1NIAID NIH HHS K24 AI064086NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI046995NIAID NIH HHS R01 AI064060NIH HHS P51 OD011132Wellcome Trust
6 · The paper itself

Abstract

unlabelledHLA-B*57:01 and HLA-B*57:03, the most prevalent HLA-B*57 subtypes in Caucasian and African populations, respectively, are the HLA alleles most protective against HIV disease progression. Understanding the mechanisms underlying this immune control is of critical importance, yet they remain unclear. Unexplained differences are observed in the impact of the dominant cytotoxic T lymphocyte (CTL) response restricted by HLA-B*57:01 and HLA-B*57:03 in chronic infection on the Gag epitope KAFSPEVIPMF (KF11; Gag 162 to 172). We previously showed that the HLA-B*57:03-KF11 response is associated with a >1-log-lower viral setpoint in C clade virus infection and that this response selects escape mutants within the epitope. We first examined the relationship of KF11 responses in B clade virus-infected subjects with HLA-B*57:01 to immune control and observed that a detectable KF11 response was associated with a >1-log-higher viral load (P = 0.02). No evidence of HLA-B*57:01-KF11-associated selection pressure was identified in previous comprehensive analyses of >1,800 B clade virus-infected subjects. We then studied a B clade virus-infected cohort in Barbados, where HLA-B*57:03 is highly prevalent. In contrast to findings for B clade virus-infected subjects expressing HLA-B*57:01, we observed strong selection pressure driven by the HLA-B*57:03-KF11 response for the escape mutation S173T. This mutation reduces recognition of virus-infected cells by HLA-B*57:03-KF11 CTLs and is associated with a >1-log increase in viral load in HLA-B*57:03-positive subjects (P = 0.009). We demonstrate functional constraints imposed by HIV clade relating to the residue at Gag 173 that explain the differential clade-specific escape patterns in HLA-B*57:03 subjects. Further studies are needed to evaluate the role of the KF11 response in HLA-B*57:01-associated HIV disease protection. IMPORTANCE: HLA-B*57 is the HLA class I molecule that affords the greatest protection against disease progression in HIV infection. Understanding the key mechanism(s) underlying immunosuppression of HIV is of importance in guiding therapeutic and vaccine-related approaches to improve the levels of HIV control occurring in nature. Numerous mechanisms have been proposed to explain the HLA associations with differential HIV disease outcome, but no consensus exists. These studies focus on two subtypes of HLA-B*57 prevalent in Caucasian and African populations, HLA-B*57:01 and HLA-B*57:03, respectively. These alleles appear equally protective against HIV disease progression. The CTL epitopes presented are in many cases identical, and the dominant response in chronic infection in each case is to the Gag epitope KF11. However, there the similarity ends. This study sought to better understand the reasons for these differences and what they teach us about which immune responses contribute to immune control of HIV infection.

Indexed as

Immune EvasionAdultCohort StudiesEpitopesFemalegag Gene Products, Human Immunodeficiency VirusGenotypeHIV InfectionsHLA-B AntigensHumansMaleMiddle AgedMutation, MissenseSelection, GeneticT-Lymphocytes, CytotoxicEpitopesgag Gene Products, Human Immunodeficiency VirusHLA-B57 antigenHLA-B Antigens

Identifiers

PMID24501417
PMCPMC3993828
OpenAlexW2121487910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.